# **Product** Data Sheet

## **TCS2002**

Cat. No.: HY-10096

CAS No.: 1005201-24-0 Molecular Formula:

Molecular Weight: 338.38 GSK-3 Target:

Pathway: PI3K/Akt/mTOR; Stem Cell/Wnt

 $C_{18}H_{14}N_2O_3S$ 

-20°C, protect from light, stored under nitrogen Storage:

\* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under

nitrogen)

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 34 mg/mL (100.48 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.9553 mL	14.7763 mL	29.5526 mL
	5 mM	0.5911 mL	2.9553 mL	5.9105 mL
	10 mM	0.2955 mL	1.4776 mL	2.9553 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3 $\beta$  inhibitor with the IC<sub>50</sub> of 35 nM.

TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research

of Alzheimer's disease<sup>[1]</sup>.

IC<sub>50</sub> & Target GSK-3

35 nM (IC<sub>50</sub>)

In Vivo TCS2002 (Compound 9b) (1-3 mg/kg;1-24 hours; GS rats and C57BL/6N mice) exhibits good pharmacokinetic profiles and favor able BBB permeability with  $AUC_{0-24h}$  value is 734 ng•h/g and  $K_p$  value (ratio of brain and plasma) is  $1.6^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: IGS rats (male, 8 weeks old)<sup>[1]</sup> Dosage: 1 and 3mg/kg

Administration:	Intravenous injection and oral administration; for 1, 2, 4, 8, 24 hours.				
Result:	comp	(S)-9b	(S)-9c		
	V <sub>DSS,iv</sub> (mL/kg)	1134	1650		
	CL <sub>total,iv</sub> (mL/min/kg)	27.4	28.4		
	C <sub>max,po</sub> (ng/mL)	396.9	289.6		
	AUC <sub>0-24 h,po</sub> (ng∙h/mL)	1380.6	1229.1		
	MRT <sub>po</sub> (h)	2.19	3.03		
	F <sup>d</sup> (%)	72.8	65.5		

#### **REFERENCES**

[1]. Morihisa Saitoh, et al. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability. J Med Chem. 2009 Oct 22;52(20):6270-86.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA